Mishra, KBarki, SSreen, ASaravagi, GKumar, S2024-12-072024-12-072024-07Mishra K, Barki S, Sreen A, Saravagi G, Kumar S. A rare incidence of cerebral venous thrombosis in a case of immune thrombocytopenia on eltrombopag . Annals of the National Academy of Medical Sciences (India). 2024 Jul; 60(3): 225-2270379-038X2454-5635https://imsear.searo.who.int/handle/123456789/241069Immune Thrombocytopenia (ITP) typically presents with mucocutaneous bleeding. Splenectomy, rituximab, and thrombopoietin receptor agonists (TPO-RAs) are the recommended second-line therapy. Eltrombopag is one of the TPO-RAs used for the treatment of steroid-refractory ITP, with a response rate of 70–80%. Though rare, yet various cases of venous thromboembolism have been reported from clinical trials as well as real-world studies. We present a case of ITP that was refractory to corticosteroid and second-line drugs; however, it responded to eltrombopag. While having a complete response on eltrombopag, the patient developed Cerebral Venous Thrombosis.Cerebral venous thrombosisCVTEltrombopagImmune thrombocytosisITPJournal ArticleIndiaDepartment of Hematology, Army Hospital (Research and Referral), New Delhi, IndiaDepartment of Neurology, Army Hospital (Research and Referral), New Delhi, IndiaDepartment of Neurology, Army Hospital (Research and Referral), New Delhi, IndiaDepartment of Radiodiagnosis and Interventional Radiology, Army Hospital (Research and Referral), New Delhi, IndiaDepartment of Hematology, Army Hospital (Research and Referral), New Delhi, India